<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="interaction" /><meta name="keywords" content="" /><title>Ciclosporin: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="bnf_int499-ciclosporin.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="bnf_int499-ciclosporin.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=bnf_int499-ciclosporin.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP8848-interactions.htm">Appendix 1 Interactions</a> &gt; <a href="PHP8852-list-of-drug-interactions.htm">List of drug interactions</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="bnf_int1160-certolizumab-pegol.htm" title="Previous: Certolizumab pegol">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="bnf_int940-cilostazol.htm" title="Next: Cilostazol">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1>Ciclosporin</h1><?highlighter on?><div id="pC" class="jN"><p><strong>Ciclosporin</strong> has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int2-ace-inhibitors.htm">ACE Inhibitors</a></td><td class="cAI"><p><span>increased risk of hyperkalaemia when </span> <span>ciclosporin</span> <span>given with</span> <span>ACE inhibitors</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int551-acetazolamide.htm">Acetazolamide</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>ciclosporin</span> <span>possibly increased by</span> <span>acetazolamide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int392-aciclovir.htm">Aciclovir</a></td><td><p><span>increased risk of nephrotoxicity when </span> <span>ciclosporin</span> <span>given with</span> <span>aciclovir</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to topical aciclovir preparations</p></div></td></tr><tr><td><a href="bnf_int1099-aliskiren.htm">Aliskiren</a></td><td class="cAI"><p><span></span> <span>ciclosporin</span> <span>increases plasma concentration of</span> <span>aliskiren</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int22-allopurinol.htm">Allopurinol</a></td><td><p><span>plasma concentration of </span> <span>ciclosporin</span> <span>possibly increased by</span> <span>allopurinol</span> <span>(risk of nephrotoxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int128-aminoglycosides.htm">Aminoglycosides</a></td><td class="cAI"><p><span>increased risk of nephrotoxicity when </span> <span>ciclosporin</span> <span>given with</span> <span>aminoglycosides</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td><p><span>plasma concentration of </span> <span>ciclosporin</span> <span>possibly increased by</span> <span>amiodarone</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int290-amphotericin.htm">Amphotericin</a></td><td class="cAI"><p><span>increased risk of nephrotoxicity when </span> <span>ciclosporin</span> <span>given with</span> <span>amphotericin</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Close monitoring required with concomitant administration of nephrotoxic drugs or cytotoxics</p></div></td></tr><tr><td><a href="bnf_int107-angiotensin-ii-receptor-antagonists.htm">Angiotensin-II Receptor Antagonists</a></td><td class="cAI"><p><span>increased risk of hyperkalaemia when </span> <span>ciclosporin</span> <span>given with</span> <span>angiotensin-II receptor antagonists</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>ciclosporin</span> <span>possibly increased by</span> <span>atazanavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int596-bezafibrate.htm">Bezafibrate</a></td><td><p><span>increased risk of renal impairment when </span> <span>ciclosporin</span> <span>given with</span> <span>bezafibrate</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int943-bosentan.htm">Bosentan</a></td><td class="cAI"><p><span></span> <span>ciclosporin</span> <span>increases plasma concentration of</span> <span>bosentan</span> <span>(also plasma concentration of <span>ciclosporin</span> reduced—avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span>metabolism of </span> <span>ciclosporin</span> <span>accelerated by</span> <span>carbamazepine</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int445-carvedilol.htm">Carvedilol</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>ciclosporin</span> <span>increased by</span> <span>carvedilol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int947-caspofungin.htm">Caspofungin</a></td><td class="cAI"><p><span></span> <span>ciclosporin</span> <span>increases plasma concentration of</span> <span>caspofungin</span> <span>(manufacturer of <span>caspofungin</span> recommends monitoring liver enzymes)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int158-chloramphenicol.htm">Chloramphenicol</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>ciclosporin</span> <span>possibly increased by</span> <span>chloramphenicol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int335-chloroquine-and-hydroxychloroquine.htm">Chloroquine and Hydroxychloroquine</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>ciclosporin</span> <span>increased by</span> <span>chloroquine and hydroxychloroquine</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>ciclosporin</span> <span>possibly increased by</span> <span>cimetidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td class="cAI"><p><span>metabolism of </span> <span>ciclosporin</span> <span>inhibited by</span> <span>clarithromycin</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int483-colchicine.htm">Colchicine</a></td><td class="cAI"><p><span>possible increased risk of nephrotoxicity and myotoxicity when </span> <span>ciclosporin</span> <span>given with</span> <span>colchicine</span> <span>—suspend or reduce dose of <span>colchicine</span> (avoid concomitant use in hepatic or renal impairment)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1108-colesevelam.htm">Colesevelam</a></td><td class="cAI"><p><span>absorption of </span> <span>ciclosporin</span> <span>reduced by</span> <span>colesevelam</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Other drugs should be taken at least 4 hours before or after colesevelam to reduce possible interference with absorption </p></div></td></tr><tr><td><a href="bnf_int1120-dabigatran-etexilate.htm">Dabigatran Etexilate</a></td><td class="cAI"><p><span></span> <span>ciclosporin</span> <span>possibly increases plasma concentration of</span> <span>dabigatran etexilate</span> <span>—manufacturer of <span>dabigatran etexilate</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int579-danazol.htm">Danazol</a></td><td class="cAI"><p><span>metabolism of </span> <span>ciclosporin</span> <span>inhibited by</span> <span>danazol</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1061-daptomycin.htm">Daptomycin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span> <span>ciclosporin</span> <span>given with</span> <span>daptomycin</span> <span>(preferably avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1076-darifenacin.htm">Darifenacin</a></td><td><p><span>avoidance of </span> <span>ciclosporin</span> <span>advised by manufacturer of</span> <span>darifenacin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int64-diclofenac.htm">Diclofenac</a></td><td class="cAI"><p><span></span> <span>ciclosporin</span> <span>increases plasma concentration of</span> <span>diclofenac</span> <span>(halve dose of <span>diclofenac</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td class="cAI"><p><span></span> <span>ciclosporin</span> <span>increases plasma concentration of</span> <span>digoxin</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int468-diltiazem.htm">Diltiazem</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>ciclosporin</span> <span>increased by</span> <span>diltiazem</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int544-diuretics-potassium-sparing-and-aldosterone-antagonists.htm">Diuretics, Potassium-sparing and Aldosterone Antagonists</a></td><td class="cAI"><p><span>increased risk of hyperkalaemia when </span> <span>ciclosporin</span> <span>given with</span> <span>potassium-sparing diuretics and aldosterone antagonists</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int525-diuretics-thiazide-and-related.htm">Diuretics, Thiazide and related</a></td><td><p><span>increased risk of nephrotoxicity and possibly hypermagnesaemia when </span> <span>ciclosporin</span> <span>given with</span> <span>thiazides and related diuretics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int516-docetaxel.htm">Docetaxel</a></td><td><p><span>in vitro studies suggest a possible interaction between </span> <span>ciclosporin</span> <span>and</span> <span>docetaxel</span> <span>(consult <span>docetaxel</span> product literature)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int506-doxorubicin.htm">Doxorubicin</a></td><td class="cAI"><p><span>increased risk of neurotoxicity when </span> <span>ciclosporin</span> <span>given with</span> <span>doxorubicin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int874-efavirenz.htm">Efavirenz</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>ciclosporin</span> <span>possibly reduced by</span> <span>efavirenz</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1030-epirubicin.htm">Epirubicin</a></td><td class="cAI"><p><span></span> <span>ciclosporin</span> <span>increases plasma concentration of</span> <span>epirubicin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td class="cAI"><p><span>metabolism of </span> <span>ciclosporin</span> <span>inhibited by</span> <span>erythromycin</span> <span>(increased plasma concentration)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int1031-etoposide.htm">Etoposide</a></td><td><p><span></span> <span>ciclosporin</span> <span>possibly increases plasma concentration of</span> <span>etoposide</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1169-everolimus.htm">Everolimus</a></td><td class="cAI"><p><span></span> <span>ciclosporin</span> <span>increases plasma concentration of</span> <span>everolimus</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int970-ezetimibe.htm">Ezetimibe</a></td><td class="cAI"><p><span>plasma concentration of both drugs may increase when </span> <span>ciclosporin</span> <span>given with</span> <span>ezetimibe</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int598-fenofibrate.htm">Fenofibrate</a></td><td><p><span>increased risk of renal impairment when </span> <span>ciclosporin</span> <span>given with</span> <span>fenofibrate</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1226-fidaxomicin.htm">Fidaxomicin</a></td><td><p><span>avoidance of </span> <span>ciclosporin</span> <span>advised by manufacturer of</span> <span>fidaxomicin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int301-fluconazole.htm">Fluconazole</a></td><td class="cAI"><p><span>metabolism of </span> <span>ciclosporin</span> <span>inhibited by</span> <span>fluconazole</span> <span>(increased plasma concentration)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> In general, fluconazole interactions relate to multiple-dose treatment</p></div></td></tr><tr><td><a href="bnf_int1019-fosamprenavir.htm">Fosamprenavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>ciclosporin</span> <span>increased by</span> <span>fosamprenavir</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Fosamprenavir is a prodrug of amprenavir</p></div></td></tr><tr><td><a href="bnf_int829-grapefruit-juice.htm">Grapefruit Juice</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>ciclosporin</span> <span>increased by</span> <span>grapefruit juice</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int291-griseofulvin.htm">Griseofulvin</a></td><td><p><span>plasma concentration of </span> <span>ciclosporin</span> <span>possibly reduced by</span> <span>griseofulvin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1164-idarubicin.htm">Idarubicin</a></td><td class="cAI"><p><span></span> <span>ciclosporin</span> <span>increases plasma concentration of</span> <span>idarubicin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int933-imatinib.htm">Imatinib</a></td><td><p><span>plasma concentration of </span> <span>ciclosporin</span> <span>possibly increased by</span> <span>imatinib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>ciclosporin</span> <span>increased by</span> <span>indinavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td class="cAI"><p><span>metabolism of </span> <span>ciclosporin</span> <span>inhibited by</span> <span>itraconazole</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td class="cAI"><p><span>metabolism of </span> <span>ciclosporin</span> <span>inhibited by</span> <span>ketoconazole</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int866-lanreotide.htm">Lanreotide</a></td><td><p><span>plasma concentration of </span> <span>ciclosporin</span> <span>reduced by</span> <span>lanreotide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int846-lercanidipine.htm">Lercanidipine</a></td><td class="cAI"><p><span>combination of </span> <span>ciclosporin</span> <span>with</span> <span>lercanidipine</span> <span>may increase plasma concentration of either drug (or both)—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int166-macrolides.htm">Macrolides</a></td><td class="cAI"><p><span>metabolism of </span> <span>ciclosporin</span> <span>possibly inhibited by</span> <span>macrolides</span> <span>(increased plasma concentration)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> See also Telithromycin</p></div></td></tr><tr><td><a href="bnf_int1142-mannitol.htm">Mannitol</a></td><td><p><span>possible increased risk of nephrotoxicity when </span> <span>ciclosporin</span> <span>given with</span> <span>mannitol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int503-melphalan.htm">Melphalan</a></td><td class="cAI"><p><span>increased risk of nephrotoxicity when </span> <span>ciclosporin</span> <span>given with</span> <span>melphalan</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int511-methotrexate.htm">Methotrexate</a></td><td class="cAI"><p><span>risk of toxicity when </span> <span>ciclosporin</span> <span>given with</span> <span>methotrexate</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int492-methylprednisolone.htm">Methylprednisolone</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>ciclosporin</span> <span>increased by high-dose</span> <span>methylprednisolone</span> <span>(risk of convulsions)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int613-metoclopramide.htm">Metoclopramide</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>ciclosporin</span> <span>increased by</span> <span>metoclopramide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1125-micafungin.htm">Micafungin</a></td><td><p><span>plasma concentration of </span> <span>ciclosporin</span> <span>possibly increased by</span> <span>micafungin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int299-miconazole.htm">Miconazole</a></td><td class="cAI"><p><span>metabolism of </span> <span>ciclosporin</span> <span>possibly inhibited by</span> <span>miconazole</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1173-mifamurtide.htm">Mifamurtide</a></td><td><p><span>avoidance of </span> <span>ciclosporin</span> <span>advised by manufacturer of</span> <span>mifamurtide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1165-mitoxantrone.htm">Mitoxantrone</a></td><td><p><span></span> <span>ciclosporin</span> <span>reduces excretion of</span> <span>mitoxantrone</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int847-modafinil.htm">Modafinil</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>ciclosporin</span> <span>reduced by</span> <span>modafinil</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int60-nsaids.htm">NSAIDs</a></td><td class="cAI"><p><span>increased risk of nephrotoxicity when </span> <span>ciclosporin</span> <span>given with</span> <span>NSAIDs</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> See also Aspirin. Interactions do not generally apply to topical NSAIDs
</p></div></td></tr><tr><td><a href="bnf_int842-nelfinavir.htm">Nelfinavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>ciclosporin</span> <span>possibly increased by</span> <span>nelfinavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int474-nicardipine.htm">Nicardipine</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>ciclosporin</span> <span>increased by</span> <span>nicardipine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int475-nifedipine.htm">Nifedipine</a></td><td><p><span></span> <span>ciclosporin</span> <span>possibly increases plasma concentration of</span> <span>nifedipine</span> <span>(increased risk of toxicity including gingival hyperplasia)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int584-octreotide.htm">Octreotide</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>ciclosporin</span> <span>reduced by</span> <span>octreotide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int636-oestrogens.htm">Oestrogens</a></td><td><p><span>plasma concentration of </span> <span>ciclosporin</span> <span>possibly increased by</span> <span>oestrogens</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a></p></div></td></tr><tr><td><a href="bnf_int752-omeprazole.htm">Omeprazole</a></td><td><p><span>plasma concentration of </span> <span>ciclosporin</span> <span>possibly affected by</span> <span>omeprazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int856-orlistat.htm">Orlistat</a></td><td class="cAI"><p><span>absorption of </span> <span>ciclosporin</span> <span>possibly reduced by</span> <span>orlistat</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int900-oxcarbazepine.htm">Oxcarbazepine</a></td><td><p><span>plasma concentration of </span> <span>ciclosporin</span> <span>possibly reduced by</span> <span>oxcarbazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td class="cAI"><p><span>metabolism of </span> <span>ciclosporin</span> <span>accelerated by</span> <span>phenobarbital</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span>metabolism of </span> <span>ciclosporin</span> <span>accelerated by</span> <span>phenytoin</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int189-polymyxins.htm">Polymyxins</a></td><td class="cAI"><p><span>increased risk of nephrotoxicity when </span> <span>ciclosporin</span> <span>given with</span> <span>polymyxins</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1060-posaconazole.htm">Posaconazole</a></td><td class="cAI"><p><span>metabolism of </span> <span>ciclosporin</span> <span>inhibited by</span> <span>posaconazole</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int662-potassium-salts.htm">Potassium Salts</a></td><td class="cAI"><p><span>increased risk of hyperkalaemia when </span> <span>ciclosporin</span> <span>given with</span> <span>potassium salts</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Includes salt substitutes</p></div></td></tr><tr><td><a href="bnf_int486-prednisolone.htm">Prednisolone</a></td><td><p><span></span> <span>ciclosporin</span> <span>increases plasma concentration of</span> <span>prednisolone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int664-progestogens.htm">Progestogens</a></td><td><p><span>plasma concentration of </span> <span>ciclosporin</span> <span>possibly increased by</span> <span>progestogens</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a href="PHP4944-oral-progestogen-only-contraceptives.htm#PHP4945">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a href="PHP4960-parenteral-progestogen-only-contraceptives.htm#PHP4965">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a href="PHP4973-intra-uterine-progestogen-only-device.htm#PHP4974">section 7.3.2.3</a>; hormonal emergency contraception, see also <a href="PHP5019-hormonal-methods.htm#PHP5024">section 7.3.5</a></p></div></td></tr><tr><td><a href="bnf_int125-propafenone.htm">Propafenone</a></td><td><p><span>plasma concentration of </span> <span>ciclosporin</span> <span>possibly increased by</span> <span>propafenone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int193-quinolones.htm">Quinolones</a></td><td class="cAI"><p><span>increased risk of nephrotoxicity when </span> <span>ciclosporin</span> <span>given with</span> <span>quinolones</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1147-ranolazine.htm">Ranolazine</a></td><td><p><span></span> <span>ciclosporin</span> <span>possibly increases plasma concentration of</span> <span>ranolazine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int855-repaglinide.htm">Repaglinide</a></td><td><p><span></span> <span>ciclosporin</span> <span>possibly enhances hypoglycaemic effect of</span> <span>repaglinide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>metabolism of </span> <span>ciclosporin</span> <span>accelerated by</span> <span>rifampicin</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>ciclosporin</span> <span>possibly increased by</span> <span>ritonavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int974-rosuvastatin.htm">Rosuvastatin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span> <span>ciclosporin</span> <span>given with</span> <span>rosuvastatin</span> <span>(avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>plasma concentration of both drugs increased when </span> <span>ciclosporin</span> <span>given with</span> <span>saquinavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1065-sevelamer.htm">Sevelamer</a></td><td><p><span>plasma concentration of </span> <span>ciclosporin</span> <span>possibly reduced by</span> <span>sevelamer</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int921-sirolimus.htm">Sirolimus</a></td><td><p><span></span> <span>ciclosporin</span> <span>increases plasma concentration of</span> <span>sirolimus</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>ciclosporin</span> <span>reduced by</span> <span>St John's wort</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int600-statins.htm">Statins</a></td><td class="cAI"><p><span>increased risk of myopathy when </span> <span>ciclosporin</span> <span>given with</span> <span>statins</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int206-sulfadiazine.htm">Sulfadiazine</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>ciclosporin</span> <span>possibly reduced by</span> <span>sulfadiazine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int689-sulfinpyrazone.htm">Sulfinpyrazone</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>ciclosporin</span> <span>reduced by</span> <span>sulfinpyrazone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int203-sulfonamides.htm">Sulfonamides</a></td><td class="cAI"><p><span>increased risk of nephrotoxicity when </span> <span>ciclosporin</span> <span>given with</span> <span>sulfonamides</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>ciclosporin</span> <span>increased by</span> <span>tacrolimus</span> <span>(increased risk of nephrotoxicity)—avoid concomitant use</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td class="cAI"><p><span>plasma concentration of both drugs increased when </span> <span>ciclosporin</span> <span>given with</span> <span>telaprevir</span> <span>(reduce dose of <span>ciclosporin</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>ciclosporin</span> <span>possibly increased by</span> <span>telithromycin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int292-terbinafine.htm">Terbinafine</a></td><td><p><span>plasma concentration of </span> <span>ciclosporin</span> <span>possibly reduced by</span> <span>terbinafine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1203-ticagrelor.htm">Ticagrelor</a></td><td><p><span>plasma concentration of </span> <span>ciclosporin</span> <span>possibly increased by</span> <span>ticagrelor</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int217-trimethoprim.htm">Trimethoprim</a></td><td class="cAI"><p><span>increased risk of nephrotoxicity when </span> <span>ciclosporin</span> <span>given with</span> <span>trimethoprim</span> <span>, also plasma concentration of <span>ciclosporin</span> reduced by intravenous<span>trimethoprim</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int812-ursodeoxycholic-acid.htm">Ursodeoxycholic Acid</a></td><td class="cAI"><p><span>absorption of </span> <span>ciclosporin</span> <span>increased by</span> <span>ursodeoxycholic acid</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int218-vancomycin.htm">Vancomycin</a></td><td class="cAI"><p><span>increased risk of nephrotoxicity when </span> <span>ciclosporin</span> <span>given with</span> <span>vancomycin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int467-verapamil.htm">Verapamil</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>ciclosporin</span> <span>increased by</span> <span>verapamil</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1134-vitamin-e.htm">Vitamin E</a></td><td><p><span>plasma concentration of </span> <span>ciclosporin</span> <span>possibly affected by</span> <span>vitamin E</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td class="cAI"><p><span>metabolism of </span> <span>ciclosporin</span> <span>inhibited by</span> <span>voriconazole</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr></tbody></table></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="bnf_int1160-certolizumab-pegol.htm">Previous: Certolizumab pegol</a> | <a class="top" href="bnf_int499-ciclosporin.htm#">Top</a> | <a accesskey="]" href="bnf_int940-cilostazol.htm">Next: Cilostazol</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>